Angiotensin II receptor antagonist: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (Unified ARB and ACE) |
imported>Robert Badgett mNo edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
==Mechanism of action== | ==Mechanism of action== | ||
'''Angiotensin II receptor antagonists''' block [[angiotensin]] II AT<sub>1</sub> receptors, in contrast to [[Angiotensin II converting enzyme inhibitors]], which block the conversion of angiotensin I to the hypertensive [[angiotensin II]]. Along with [[Angiotensin-converting enzyme inhibitor]]s, they act on the [[renin]]-angiotensin system; the two classes may be used synergistically. | '''Angiotensin II receptor antagonists''' block [[angiotensin]] II AT<sub>1</sub> receptors or ARBs, in contrast to [[Angiotensin II converting enzyme inhibitors]], which block the conversion of angiotensin I to the hypertensive [[angiotensin II]]. Along with [[Angiotensin-converting enzyme inhibitor]]s, they act on the [[renin]]-angiotensin system; the two classes may be used synergistically. | ||
==Applications== | ==Applications== | ||
Revision as of 21:51, 14 May 2008
Mechanism of action
Angiotensin II receptor antagonists block angiotensin II AT1 receptors or ARBs, in contrast to Angiotensin II converting enzyme inhibitors, which block the conversion of angiotensin I to the hypertensive angiotensin II. Along with Angiotensin-converting enzyme inhibitors, they act on the renin-angiotensin system; the two classes may be used synergistically.
Applications
These drugs are primarily antihypertensives. They may also be used to protect the kidneys.
Adverse effects
Angiotensin II receptor antagonists can cause hyperkalemia. The rise in potassium has been reported to be both similar to[1] and less that occurs with angiotensin-converting enzyme inhibitors.[2]
References
- ↑ The ONTARGET Investigators. 2008. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 358, no. 15:1547-1559.
- ↑ Bakris GL, Siomos M, Richardson D, et al (2000). "ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group". Kidney Int. 58 (5): 2084–92. DOI:10.1111/j.1523-1755.2000.00381.x. PMID 11044229. Research Blogging.